Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older. EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older ( 1 ) FDA label
Cannabidiol · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Cannabidiol | DRUG | Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant. |
Cannabidiol is being studied as an investigational treatment for menstrual discomfort. Canopy Growth Corporation is developing it for this pain indication, and it has completed a Phase 2 trial in that setting. It is not an approved therapy for menstrual discomfort.
Cannabidiol targets CNR1, the cannabinoid receptor type 1. It acts as a negative allosteric modulator at this receptor, meaning it binds to a site distinct from the primary binding site and reduces receptor signaling. This mechanism is being explored in the context of menstrual discomfort.
Canopy Growth Corporation is developing Cannabidiol for menstrual discomfort. The company trades on the stock exchange under the ticker CGC. The drug is a small molecule in Phase 2 clinical development for this indication.
Cannabidiol is in Phase 2 development for menstrual discomfort. One Phase 2 trial has been completed, and no active trials are currently listed. It remains an investigational drug and has not been approved for this use.
Cannabidiol has been evaluated in a completed Phase 2 trial, NCT05679830, titled The Effects of CBD Isolate on Menstrual-Related Symptoms. The trial enrolled 33 participants and was an uncontrolled study without randomization or blinding. No other trials for this indication are listed.